CARDIO DIAGNOSTICS HOLDINGS INC (CDIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.86+1.64%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CDIO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue growing adoption and commercialization of Epi+Gen CHD and PrecisionCHD tests in US and international markets with strategic partnerships and reimbursement milestones.
Newly stated in 2026-Q2. Management emphasizes commercialization growth with US and international partnerships and reimbursement progress. Financials show revenue growth from $940K in 2025-Q1 to $5.36M in 2026-Q2, indicating early commercial traction. The trajectory shows delivering progress in market adoption.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Diversified US and international commercialization strategy with meaningful reimbursement milestones and progress.”
Leverage company-owned CLIA lab to reduce initial lab COGS by ~30% with further reductions expected as scale increases.
Newly stated in 2026-Q2. Management reports ~30% initial lab COGS reduction from in-house processing. Financials show operating losses persist with operating income at -$1.5M in 2026-Q2, indicating cost reductions are early and not yet sufficient to reach profitability. Trajectory shows limited progress on cost containment.
“Initial lab COGS reduction by ~30% with additional reduction expected with scale.”
Continue rigorous clinical studies, economic evidence, and monitoring capabilities to demonstrate utility and cost savings of tests.
Newly stated in 2026-Q2. Management emphasizes expanding clinical and economic evidence for tests. Financials show revenue growth but continued net losses, indicating clinical validation is progressing but not yet translating into profitability. Trajectory is delivering early evidence base expansion.
“Ongoing studies for interventions, new modalities, and cost savings & ROI to demonstrate financial impact.”
Achieve and expand reimbursement milestones such as CPT codes, CMS payment rates, in-network coverage, and pursue Medicare coverage determination.
Newly stated in 2026-Q2. Management highlights reimbursement milestones including $854 CMS payment rate set in December 2025 and in-network coverage started in June 2026. Financials show revenue growth consistent with reimbursement progress. Trajectory is delivering reimbursement expansion.
“Completed CPT PLA codes, CMS payment rate set, in-network coverage started, pursuing Medicare coverage determination.”
Over the trailing year it converted 0.65x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
3 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.